Litigation Details for Pfizer, Inc. v. All (10th Cir. 2020)
✉ Email this page to a colleague
Pfizer, Inc. v. All (10th Cir. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-03-12 |
| Court | Court of Appeals for the Tenth Circuit | Date Terminated | 2020-05-26 |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Parties | HEATHER BRESCH, CEO OF MYLAN N.V. | ||
| Patents | 7,449,012; 7,794,432 | ||
| Attorneys | Lynn Lincoln Sarko | ||
| Firms | Direct: 202-637-5573, Hogan Lovells, Firm: 202/637-5600 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Pfizer, Inc. v. All
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Pfizer, Inc. v. All (10th Cir. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-03-12 | 10110319201 | Petition for permission to appeal | sued Teva for infringing U.S. Patent No. 7,449,012 (“the Teva patent litigation”). In November 2010,… Patent Infringement Lawsuits The Pfizer defendants own the patents protecting the… end, defendants allegedly added patents to the already-patented EpiPen to stop generic competitors.…secured ’432 patent. Later, King and Meridian dropped their claims based on the ’012 patent, leaving only…claims for the ’432 patent. On April 27, 2012, the parties settled the Teva patent litigation. According | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
